Silverback Therapeutics

📍 Seattle, United States🗓 Founded 2016👥 13 employees💰 Last funded Sep 2020
Biotechnology Research🌐 silverbacktx.com
Website LinkedIn
We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Silverback Therapeutics?
Silverback Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Silverback Therapeutics last raise funding?
The most recent investment in Silverback Therapeutics recorded on gritt.io was in September 2020.
When was Silverback Therapeutics founded?
Silverback Therapeutics was founded in 2016.
What industry is Silverback Therapeutics in?
Silverback Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Silverback Therapeutics based?
Silverback Therapeutics is headquartered in Seattle, United States.